Cosmetic peptide INCI: documents buyers should request

Hytan Peptides editorial desk · 22 October 2026 · Cosmetic ingredient procurement

A cosmetic peptide quotation should identify both the peptide and the material actually delivered. An INCI name identifies an ingredient for cosmetic labelling; it does not establish the peptide concentration, the carrier composition or permission to sell a finished product. Before comparing prices, obtain a composition statement that connects the INCI declaration, chemical identity and batch specification.

Connect the INCI name to the supplied material

International Nomenclature of Cosmetic Ingredients, or INCI, provides a naming system for cosmetic ingredients. A supplier’s trade name, peptide abbreviation and INCI declaration can describe different aspects of one commercial material. Copying the most familiar name from a catalogue leaves that relationship unresolved.

Ask the manufacturer to identify the precise chemical form behind the name. For a peptide, this can include the sequence, terminal modifications, salt form or metal complex where relevant. A CAS number is a useful cross-check when one has been assigned to the material, but it should agree with the identity statement. It cannot replace that statement.

For example, the name on a GHK-Cu research material page should not be copied into a cosmetic formula dossier as evidence of an approved cosmetic ingredient. Establish the intended cosmetic identity and the commercial grade separately.

A peptide solution needs a complete composition statement

A powder and a diluted commercial solution can share a peptide identifier while containing very different amounts of peptide per kilogram purchased. Water, humectants, buffers and preservatives also become part of the formulation review. An HPLC area percentage for the peptide fraction does not describe the complete mixture.

Request the peptide assay on an explicitly stated basis: mass fraction in the delivered material, dry basis, or another defined basis. Then reconcile that figure with the formulation supplied to the buyer. Where exact percentages are confidential, agree a controlled disclosure to the customer’s safety assessor or another suitable recipient.

• Identify every intentionally added carrier and preservative, with its declared name.
• State the peptide concentration and whether the result describes the material as supplied.
• Declare the relevant counter-ion, complexing component or buffer system.
• Record which composition details are fixed and which may vary within an agreed range.

Use CosIng as an information source, with its stated limits

The European Commission’s CosIng database notice explicitly separates an ingredient name from approval for cosmetic use. An entry is information for the review; the Cosmetics Regulation, its annexes and the finished-product safety assessment determine what the project must satisfy.

For EU labelling, Article 19(1)(g) and Article 33 link ingredient declarations to common ingredient names. The Commission’s glossary page lists Implementing Decision (EU) 2025/1175 and explains the naming framework. That is a reason to check the current glossary when artwork is approved, rather than relying indefinitely on an old supplier PDF.

Preserve the source record, access date and assessor’s conclusion in the project file. A screenshot saying that a name was found answers a narrower question than whether the proposed formulation and claims are acceptable in its destination market.

Build a dossier that the formulator can actually use

The useful dossier follows the decisions the buyer must make. Identity and composition support ingredient selection. A specification defines release requirements. Batch results show whether a particular delivery meets them. Safety and handling information have their own purpose. Combining these into a single generic certificate makes omissions difficult to spot.

1. Obtain an identity and composition declaration that names the commercial grade and revision.
2. Review the specification, including assay basis, relevant impurities and microbiological requirements.
3. Match the COA lot number to the delivered packaging and manufacturing record identifiers.
4. Collect the SDS, storage guidance and any formulation compatibility information relevant to the project.
5. Route the material’s safety information and intended use to the responsible qualified assessor.

Missing information should become a specific request. For instance, ask whether the assay includes the carrier mass. Asking for a “better COA” gives the supplier no clear question to answer.

Carry the identity review into repeat orders

A successful sample does not permanently qualify every material sold under the same trade name. A change in peptide concentration, preservative, salt form or manufacturing site can affect an existing formula and its documentation. Put the supplier’s change-notification responsibilities into the supply agreement before repeat commercial orders begin.

Keep the approved composition revision with the retained sample and the customer’s material code. Purchasing can then check a new quotation against the approved version instead of reviewing the name alone. The formulator should decide whether a notified change requires a new compatibility study, stability work, artwork review or safety reassessment.

Hytanbio’s cosmetic peptide and OEM/ODM project overview describes the supported formats. For an enquiry, provide the intended market, ingredient identity and the documentation your project still needs. These details make the scope of the material review clear.

References

• European Commission: cosmetic ingredient database and important notice
• European Commission: common ingredient-name glossary and relevant legislation